PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2015.0892016482499-507Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast CancerChanghoon Yoo, Sung-Bae Kim, Jungsil Ro, Seock-Ah Im, Young-Hyuck Im, Jee Hyun Kim, Jin-Hee Ahn, Kyung Hae Jung, Hong Suk Song, Seok Yun Kang, Hee Sook Park, Hyun-Cheol Chunghttp://e-crt.org/upload/pdf/crt-2015-089.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2015.089, http://www.e-crt.org/upload/pdf/crt-2015-089.pdf
Annals of Oncology10.1093/annonc/mdv519.05201526ix1656PD Quality of life in TSU-68 study: Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracyclineB.S. Sohn, S.B. Kim, J.-H. Ahn, K.H. Jung, K.S. Lee, J. Ro, S.-A. Im, Y.-H. Im, H.-S. Song, H.-S. Park, H.C. Chunghttps://api.elsevier.com/content/article/PII:S0923753419461553?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419461553?httpAccept=text/plain
European Journal of Cancer10.1016/s0959-8049(11)71500-3201147S3475058 POSTER Randomized Phase II Multicenter Trial of Oral Antiangiogenic Agent TSU-68 in Combination With Docetaxel Versus Docetaxel Alone in Patients With Metastatic Breast Cancer Previously Treated With an AnthracyclineS. Kim, J.H. Ahn, J. Ro, S.A. Im, Y.H. Im, J.H. Kim, H.S. Song, S.Y. Kang, H.S. Park, H.C. Chunghttps://api.elsevier.com/content/article/PII:S0959804911715003?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0959804911715003?httpAccept=text/plain
Asia-Pacific Journal of Clinical Oncology10.1111/ajco.126812017136365-371Quality of life on TSU-68: Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracyclineByeong Seok Sohn, Sung-Bae Kim, Jin-Hee Ahn, Kyung Hae Jung, Jeongeun Kim, Keun Seok Lee, Jungsil Ro, Seock-Ah Im, Young-Hyuck Im, Hong Suk Song, Hee Sook Park, Hyun-Cheol Chunghttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fajco.12681, http://onlinelibrary.wiley.com/wol1/doi/10.1111/ajco.12681/fullpdf
Investigational New Drugs10.1007/s10637-014-0093-62014324753-761Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: Randomized phase II multicenter trialSung-Bae Kim, Changhoon Yoo, Jungsil Ro, Seock-Ah Im, Young-Hyuck Im, Jee Hyun Kim, Jin-Hee Ahn, Kyung Hae Jung, Hong Suk Song, Seok Yun Kang, Hee Sook Park, Hyun-Cheol Chunghttp://link.springer.com/content/pdf/10.1007/s10637-014-0093-6.pdf, http://link.springer.com/article/10.1007/s10637-014-0093-6/fulltext.html, http://link.springer.com/content/pdf/10.1007/s10637-014-0093-6
Journal of Circulating Biomarkers10.5772/61320201549Quantification of Cell-Free HER-2 DNA in Plasma from Breast Cancer Patients: Sensitivity for Detection of Metastatic Recurrence and Gene AmplificationPatricia Diana Sørensen, Rikke Fredslund Andersen, Niels Pallisgaard, Jonna Skov Madsen, Erik Hugger Jakobsen, Ivan Brandslundhttp://journals.sagepub.com/doi/pdf/10.5772/61320, http://journals.sagepub.com/doi/full-xml/10.5772/61320, http://journals.sagepub.com/doi/pdf/10.5772/61320
Breast Cancer10.1007/s12282-012-0344-3201221120-27A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistanceMasakazu Toi, Toshiaki Saeki, Hiroji Iwata, Kenichi Inoue, Yutaka Tokuda, Yasuyuki Sato, Yoshinori Ito, Kenjiro Aogi, Yuichi Takatsuka, Hitoshi Ariokahttp://link.springer.com/content/pdf/10.1007/s12282-012-0344-3.pdf, http://link.springer.com/article/10.1007/s12282-012-0344-3/fulltext.html, http://link.springer.com/content/pdf/10.1007/s12282-012-0344-3
Clinical Breast Cancer10.1016/j.clbc.2013.11.0052014143e89-e94Antiangiogenic Therapy in Patients With HER2-Positive Metastatic Breast Cancer: A Case SeriesOlivia Le Saux, Benoît You, Gilles Freyerhttps://api.elsevier.com/content/article/PII:S1526820913002875?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1526820913002875?httpAccept=text/plain
Cancer Chemotherapy and Pharmacology10.1007/s00280-010-1320-22010672315-324A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinomaFumihiko Kanai, Haruhiko Yoshida, Ryosuke Tateishi, Shinpei Sato, Takao Kawabe, Shuntaro Obi, Yuji Kondo, Makoto Taniguchi, Kazumi Tagawa, Masafumi Ikeda, Chigusa Morizane, Takuji Okusaka, Hitoshi Arioka, Shuichiro Shiina, Masao Omatahttp://link.springer.com/content/pdf/10.1007/s00280-010-1320-2.pdf, http://link.springer.com/article/10.1007/s00280-010-1320-2/fulltext.html, http://link.springer.com/content/pdf/10.1007/s00280-010-1320-2
Clinical Breast Cancer10.3816/cbc.2008.s.01120088S151-S156Incorporation of Antiangiogenic Therapies in the Treatment of Metastatic Breast CancerFoluso O. Ademuyiwa, Kathy D. Millerhttps://api.elsevier.com/content/article/PII:S1526820911709387?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1526820911709387?httpAccept=text/plain